S

Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373

Watchlist Manager
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Watchlist
Price: 6.57 CNY 1.55% Market Closed
Market Cap: 4.3B CNY

Wall Street
Price Targets

Price Targets Summary
Shanghai MicuRx Pharmaceutical Co Ltd

There are no price targets for Shanghai MicuRx Pharmaceutical Co Ltd.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Shanghai MicuRx Pharmaceutical Co Ltd Competitors:
Price Targets
6990
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
16% Upside
ALXO
ALX Oncology Holdings Inc
159% Upside
688363
Bloomage Biotechnology Corp Ltd
6% Upside
688177
Bio-Thera Solutions Ltd
50% Upside
CPRX
Catalyst Pharmaceuticals Inc
56% Upside
301080
Acrobiosystems Co Ltd
31% Upside
2480
Beijing Luzhu Biotechnology Co Ltd
38% Upside
2142
Hbm Holdings Ltd
3% Downside

Revenue
Forecast

Revenue Estimate
Shanghai MicuRx Pharmaceutical Co Ltd

The compound annual growth rate of Shanghai MicuRx Pharmaceutical Co Ltd's revenue for the next 3 years is 24%.

N/A
Past Growth
24%
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Shanghai MicuRx Pharmaceutical Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Shanghai MicuRx Pharmaceutical Co Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Shanghai MicuRx Pharmaceutical Co Ltd's stock price target?
Not Available

Shanghai MicuRx Pharmaceutical Co Ltd doesn't have any price targets made by Wall Street professionals.

What is Shanghai MicuRx Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
24%

The compound annual growth rate of Shanghai MicuRx Pharmaceutical Co Ltd's revenue for the next 3 years is 24%.

Back to Top